Chemomab Therapeutics (CMMB)
NASDAQ:CMMB
Holding CMMB?
Track your performance easily

Chemomab Therapeutics (CMMB) Income Statement

219 Followers

Chemomab Therapeutics Income Statement

Last quarter (Q4 2023), Chemomab Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Chemomab Therapeutics's net income was $―. See Chemomab Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
------
Cost of Revenue
$ 5.14M-$ 5.14M$ -3.31M$ 777.00K-
Gross Profit
$ -5.14M-$ -5.14M$ 3.31M$ -777.00K-
Operating Expense
$ 26.01M$ 25.46M$ 28.53M$ -12.37M$ 5.97M$ -22.90M
Operating Income
$ -26.01M$ -25.46M$ -28.53M$ -12.37M$ -5.97M$ -19.55M
Net Non Operating Interest Income Expense
-$ 1.24M$ -353.00K-$ 6.00K$ 9.00K
Other Income Expense
$ -353.00K-$ -353.00K$ -345.00K$ 500.00K$ -4.57M
Pretax Income
$ -24.86M$ -24.22M$ -28.18M$ -12.37M$ -5.97M$ -22.90M
Tax Provision
$ 31.00K-$ -534.00K$ 0.00$ 0.00$ 0.00
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -25.11M$ -24.22M$ -27.65M$ -12.48M$ -5.95M$ -18.67M
Basic EPS
$ -0.80$ -0.10$ 0.12---
Diluted EPS
$ -0.80$ -0.10$ 0.12$ 0.06$ 4.96$ 12.64
Basic Average Shares
$ 675.09M$ 235.00M$ 227.59M$ 207.47M$ 2.32K$ 2.15M
Diluted Average Shares
$ 675.09M$ 235.00M$ 227.59M$ 207.97M$ 2.38M$ 1.81M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ -23.77M$ 25.46M$ 28.53M$ -15.68M$ 6.75M$ -22.90M
Net Income From Continuing And Discontinued Operation
$ -25.11M$ -24.22M$ -27.65M$ -12.48M$ -5.95M$ -18.67M
Normalized Income
------
Interest Expense
------
EBIT
$ -25.18M-$ -28.53M$ -12.37M$ -5.97M$ -22.90M
EBITDA
$ -25.13M-$ -28.48M$ -12.33M$ -5.95M$ -22.62M
Currency in USD

Chemomab Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis